Skip to main content
Premium Trial:

Request an Annual Quote

Orchid BioSciences Raises Q4 Revenue Forecast

NEW YORK, Dec. 21 – SNP scoring company Orchid BioSciences said Friday it expects its fourth-quarter revenues to exceed previous estimates by more than 30 percent as a result of additional product offerings stemming from a recent acquisition and several new deals.

"We expect to achieve top-line revenues of approximately $10 million in the fourth quarter, more than 30 percent greater than the original consensus analyst revenue estimate of approximately $7.5 million," Donald Marvin, Orchid’s chief operating officer and chief financial officer, said in a statement.

"Our strong revenues reflect the addition of Lifecodes in early December, as well as recent agreements with a number of new product and service customers and collaborators,” he said.

Orchid of Princeton, NJ, said that it expects to post revenues for the year of $28 million - $30 million, 50 percent to 65 percent higher than 2000 revenues. The company said it foresees revenues greater than $55 million in 2003.

Orchid expects to post a loss of between $1.33 and $1.38 a share for 2001.

The company will announce its fourth quarter and 2001 earnings on February 28.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.